Shanghai, China & JERSEY CITY, N.J., United States: ...

Mumbai: Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan rep ...

In an expert call, the brokerage addressed possibilities of pass-through of tariffs to consumers, and the feasibility of ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...

Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

“Automation has already been heavily utilized in many aspects of mAb manufacturing, such as process control, monitoring, and ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.